American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting

February 25 - 28, 2022

Need Help?

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person

I am a payer or formulary decision-maker

I am neither (take me to AstraZeneca.com)

American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting

HTML

Reduction in Asthma Exacerbations after Treatment with Benralizumab: Results from the ZEPHYR 2 Study

HTML

Real-world Biologic Adherence Among US Specialist-treated Adults with Severe Asthma Differs by Biologic: Results from The CHRONICLE Study

HTML

Clinical Remission with Biologic Use Among US Specialist-treated Patients with Severe Asthma: Results from the CHRONICLE Study

HTML

Impact of Clinical and Biomarker Covariates on the Ability of the Asthma Impairment and Risk Questionnaire (AIRQ®) to Predict Future Exacerbations

HTML

Lengthy Process of Biologic Approval and Administration Delays Treatment of Patients With Moderate to Severe Asthma

HTML

Clinical and Economic Burden of Patients with Severe Asthma Untreated with a Biologic in the United States, Overall and by Blood Eosinophil and Level of Asthma Control

HTML

Caregiver Treatment Preferences for Children and Adolescents With Asthma: A Discrete Choice Experiment

HTML

Patterns of High-risk Systemic Corticosteroid Exposures, Short-acting Beta2-agonist Utilization, and Adverse Health Conditions in Children with Asthma in the United States

HTML

Disease Burden Among Patients with Multiple Overlapping Eosinophilic Diseases in the REVEAL Study

HTML

Efficacy of Tezepelumab in Patients with Uncontrolled Asthma: A Pooled Analysis of the Phase 2b PATHWAY and Phase 3 NAVIGATOR Studies

HTML

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with Respiratory Comorbidities: Results from the Phase 3 NAVIGATOR Study

HTML

Tezepelumab Treatment Reduced Asthma Symptomatic Days in Adults and Adolescents with Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study

HTML

Tezepelumab Reduces Exacerbations Across All Seasons in Patients With Severe, Uncontrolled Asthma: Results From the Phase 3 NAVIGATOR Study

HTML

Tezepelumab Reduces Inflammatory Biomarkers as Early as Week 2 and Maintains Reductions Until Week 52 in the NAVIGATOR Phase 3 Severe Asthma Trial

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Welcome to AstraZeneca Medical Information

Welcome to AstraZeneca
Medical Information